Evotec (EVO) Projected to Announce Earnings on Thursday

Evotec (NASDAQ:EVO) is anticipated to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.1988) per share and revenue of $154.63 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Evotec Stock Up 2.2%

EVO stock opened at $1.60 on Thursday. The firm’s fifty day simple moving average is $1.66 and its 200-day simple moving average is $2.55. The company has a quick ratio of 2.21, a current ratio of 2.33 and a debt-to-equity ratio of 0.62. Evotec has a 12 month low of $1.33 and a 12 month high of $4.19.

Analysts Set New Price Targets

Several brokerages recently issued reports on EVO. HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Evotec in a report on Wednesday, October 14th. TD Cowen downgraded shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 target price for the company. in a research report on Wednesday, July 15th. Weiss Ratings lowered shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 25th. Finally, Berenberg Bank downgraded Evotec from a “buy” rating to a “hold” rating in a research report on Thursday, July 16th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $3.00.

Evotec Company Profile

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic research organizations. The company combines scientific expertise, proprietary technologies and integrated research platforms to identify and advance potential medicines across multiple therapeutic areas, including neuroscience, oncology, metabolic disease, infectious disease and inflammation.

Evotec’s activities span early-stage target identification, compound screening, medicinal chemistry, pharmacology, preclinical research and selected clinical development services.